PubMed Health⌕ Search

PubMed · 9416592

Managing space motion sickness.

Abstract

Space motion sickness is a well-recognized problem for space flight and affects 73% of crewmembers on the first 2 or 3 days of their initial flight. Illness severity is variable, but over half of cases are categorized as moderate to severe. Management has included elimination of provocative activities and delay of critical performance-related procedures such as extra-vehicular activity (EVA) or Shuttle landing during the first three days of missions. Pharmacological treatment strategies have had variable results, but intramuscular promethazine has been the most effective to date with a 90% initial response rate and important reduction in residual symptoms the next flight day. Oral prophylactic treatment of crewmembers with difficulty on prior flights has had mixed results. In order to accommodate more aggressive pharmacologic management, crew medical officers receive additional training in parenteral administration of medications. Preflight medication testing is accomplished to reduce the risk of unexpected performance decrements or idiosyncratic reactions. When possible, treatment is offered in the presleep period to mask potential treatment-related drowsiness. Another phenomenon noted by crewmembers and physicians as flights have lengthened is readaptation difficulty or motion sickness on return to Earth. These problems have included nausea, vomiting, and difficulty with locomotion or coordination upon early exposure to gravity. Since landing and egress are principal concerns during this portion of the flight, these deficits are of operational concern. Postflight therapy has been directed at nausea and vomiting, and meclizine and promethazine are the principal agents used. There has been no official attempt at prophylactic treatment prior to entry. Since there is considerable individual variation in postflight deficit and since adaptation from prior flights seems to persist, it has been recommended that commanders with prior shuttle landing experience be named to flights of extended duration.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

R T Jennings. Managing space motion sickness.. https://pubmed.ncbi.nlm.nih.gov/9416592/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Simultaneous determination of domperidone maleate and cinnarizine in a binary mixture using derivative ratio spectrophotometry and classical least squares calibration.

This work is concerned with the simultaneous determination of domperidone maleate (DOM) and cinnarizine (CINN) in a binary mixture form without previous separation by two different methods. The first method is the application of derivative ratio spectrophotometry where the linearity range was 2.5-30 micro g/ml, 2.5-25 micro g/ml for DOM and CINN, respectively, and percentage recoveries were 100.26+/-1.308 and 99.86+/-0.939 for DOM and CINN, respectively, in their laboratory prepared mixtures. The second method depends on the application of classical least squares (CLS) calibration model. Two training sets were constructed and the best model was used for the prediction of the concentrations of both drugs. The proposed procedures were successfully applied for the simultaneous determination of both drugs in laboratory prepared mixtures and in commercial tablet preparations. The validity of the proposed methods was assessed by applying the standard addition technique where the percentage recovery of the added standard was found to be 99.83+/-1.861 and 98.38+/-0.871 for DOM and CINN, respectively, using the derivative ratio method and 99.53+/-0.916 and 99.39+/-0.599 for DOM and CINN, respectively, using the CLS method. The proposed procedures are rapid, simple, require no preliminary separation steps and can, therefore, be used routine analysis of both drugs in quality control laboratories.

Antiemetics↗

Spectrophotometric determination of meclozine HCl and papaverine HCl in their pharmaceutical formulations.

A simple, accurate and highly sensitive spectrophotometric method is proposed for the rapid determination of meclozine and papaverine hydrochlorides using chromotrope 2B (C2B) and chromotrope 2R (C2R). The method consists of extracting the formed ion-associates into chloroform in the case of meclozine HCl and into methylene chloride in case of papaverine HCl. The ion-associates exhibit absorption maxima at 536 and 524 nm for C2B and C2R with meclozine HCl and at 540 and 528 nm with papaverine HCl, respectively. Meclozine can be determined up to 4.0 and 2.6 mg ml(-1), using C2B and C2R, respectively, while papaverine can be determined up to 1.68 and 1.37 mg ml(-1), respectively. The effect of acidity, reagent concentration, time, solvent and stoichiometric ratio of the ion-associates were studied. The molar absorptivity and Sandell sensitivity of the reaction products were calculated. The method was applied to the determination of the drugs in their pure state or pharmaceutical preparations with mean recovery values of 99.63-100.80 and 99.75-100.08% and coefficient of variation 0.945-2.210 and 1.020-1.268 for meclozine HCl and papaverine HCl, respectively.

Antiemetics↗